Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Codexis Q1 2026 Earnings Call - ECO Synthesis Revenue Surge and Stereochemistry Breakthrough
Codexis reported a sharp revenue jump in Q1 2026, driven by the full recognition of a major Merck technology transfer deal. The company is aggressively positioning its ECO Synthesis platform as the sc...
- Q1 2026 revenue doubled to $15.2 million year-over-year, primarily due to full recognition of the Merck Technology Transfer Agreement.
- The Merck deal for the HIV drug islatravir replaced a 16-step chemical synthesis with a biocatalytic cascade, earning a Green Chemistry Challenge Award.
- Product gross margin expanded significantly to 71% in Q1 2026 from 55% in the prior year period, reflecting a shift toward higher-margin product mix.
- +12 more takeaways
BioLife Solutions Q1 2026 Earnings Call - Revenue Surges 25% as Biopreservation Media Franchise Drives Growth
BioLife Solutions delivered a robust Q1 2026, with revenue jumping 25% year-over-year to $27.5 million and adjusted EBITDA up 15%. The growth was overwhelmingly fueled by its biopreservation media (BP...
- Q1 2026 revenue reached $27.5 million, a 25% year-over-year increase, driven primarily by strong demand for biopreservation media (BPM).
- Adjusted EBITDA grew approximately 15% to $6.2 million, representing 22% of revenue, though the margin declined slightly due to product mix and yield issues.
- BPM remains the dominant revenue driver, accounting for over 85% of total sales, with more than 70% market share in U.S. commercially sponsored clinical trials.
- +7 more takeaways
Expensify Q1 2026 Earnings Call - Profitability Holds While Migration Drives Growth Signal
Expensify delivered a mixed Q1 2026 print, with revenue declining 6% year-over-year to $34 million and paid members slipping 4% to 632,000. The top-line softness reflects the ongoing transition to New...
- Revenue fell 6% year-over-year to $34 million, reflecting continued top-line pressure during the platform transition.
- Paid members declined 4% to 632,000 on average, but April paid active users rose to 641,000, signaling early recovery momentum.
- Adjusted EBITDA held at $6.2 million, with non-GAAP net income of $3.6 million, underscoring margin resilience despite revenue softness.
- +7 more takeaways
Alarm.com 1st Quarter 2026 Earnings Call - SaaS Revenue Exceeds Expectations Amid Supply Chain Headwinds
Alarm.com delivered a robust first quarter for 2026, with SaaS and license revenue growing 10.8% year-over-year to $181.5 million, comfortably beating the midpoint of guidance by $5.6 million. The bea...
- SaaS and license revenue grew 10.8% year-over-year to $181.5 million, exceeding the midpoint of guidance by $5.6 million.
- Revenue retention rate hit 95.4%, a decade-high, contributing approximately $2 million to $2.5 million in quarterly upside.
- EnergyHub revenue provided a $2 million tailwind due to a structural shift pulling forward an agreement originally slated for Q3.
- +7 more takeaways
INmune Bio Q1 2026 Earnings Call - CORDStrom Nearing Approval, XPro Platform Explored for Rare Diseases
INmune Bio is accelerating its regulatory timeline for CORDStrom, the lead candidate for recessive dystrophic epidermolysis bullosa (RDEB), with a U.K. Marketing Authorisation Application (MAA) now ta...
- CORDStrom MAA submission to the U.K. MHRA is now targeted for early Q3 2026, with a global EMA and FDA submission deadline maintained for late 2026.
- The company has secured a long-term supply agreement with Anthony Nolan U.K. Cord Blood Bank to ensure consistent umbilical cord tissue for CORDStrom manufacturing.
- Process validation for CORDStrom is underway, with the first of three manufacturing runs completed and the remaining two scheduled to meet the submission deadline.
- +11 more takeaways
Outset Medical Q1 2026 Earnings Call - Margin Expansion and Cash Preservation Offset Capital Sales Lumps
Outset Medical delivered a quarter defined by operational discipline rather than top-line fireworks. Revenue dipped 6% year-over-year to $27.9 million, dragged down by the predictable lumpiness of cap...
- Revenue fell 6% year-over-year to $27.9 million, primarily due to timing shifts in capital equipment orders rather than weak demand.
- Product gross margin expanded 400 basis points to 52.4%, driven by favorable sales mix and disciplined cost management.
- Service gross margin surged 1,600 basis points to 26.7%, reflecting operational efficiency and scaling of implementation services.
- +7 more takeaways
Nano Dimension Q1 2026 Earnings Call - Strategic Monetization Accelerates Amidst $40.4M Goodwill Impairment
Nano Dimension reported a sharp strategic pivot during its Q1 2026 earnings call, accelerating a multi-phase plan to streamline operations and monetize legacy assets. The company recorded $29.7 millio...
- Revenue surged 106% year-over-year to $29.7 million, primarily fueled by the inclusion of Markforged, which contributed $17.1 million to the top line.
- Nano Dimension recorded a substantial $40.4 million non-cash goodwill impairment charge against its Markforged FFF product line, signaling a significant write-down in the unit's expected future value.
- Standalone revenue (excluding Markforged) declined approximately 12% year-over-year to $12.6 million, impacted by increased tariffs and the effects of recent divestments.
- +12 more takeaways
Power Integrations Q1 2025 Earnings Call - Data Center SAM Exceeds $1 Billion by 2030 as High-Voltage GaN Gains Traction
Power Integrations reported a solid Q1 2025, with revenue of $108.3 million, up 3% year-over-year and 5% sequentially. Industrial growth drove the top line, up 23% year-over-year, while consumer reven...
- Q1 revenue of $108.3 million beat expectations, up 3% year-over-year and 5% sequentially, driven by a 23% year-over-year surge in industrial applications.
- Consumer revenue normalized after a tariff-driven pull-in in Q1 2024, but showed a 17% sequential recovery as channel inventory cleared.
- Gross margin held steady at 53.5% (non-GAAP), while operating margin expanded to 11.7% as restructuring shifted technical marketing resources into R&D.
- +7 more takeaways
Westrock Coffee Company Q1 2026 Earnings Call - Conway Facility Drives First Operating Profit and EBITDA Surge
Westrock Coffee Company’s Q1 2026 results mark a structural inflection point as the fully operational Conway facility drives consolidated adjusted EBITDA to a record $26 million, more than tripling ye...
- Consolidated adjusted EBITDA reached a record $26 million, tripling year-over-year and marking the fourth consecutive quarter of growth.
- Net sales increased 44% to $308.8 million, driven by the full operational ramp of the Conway facility and volume growth across existing brand partners.
- The company transitioned from a $13.1 million operating loss in Q1 2025 to a $3.2 million operating profit in Q1 2026, signaling visible operating leverage.
- +9 more takeaways
Cytek Biosciences Q1 2026 Earnings Call - U.S. Rebound Offsets Geopolitical Headwinds
Cytek Biosciences reported a 6% year-over-year revenue increase to $44.1 million in Q1 2026, driven by a sharp 32% rebound in U.S. sales and double-digit growth in recurring service and reagent revenu...
- Q1 2026 revenue reached $44.1 million, a 6% year-over-year increase, led by a robust 32% rebound in U.S. sales.
- Recurring revenue (reagents and services) grew 19% year-over-year to represent 35% of total revenue on a trailing 12-month basis, highlighting the strength of the installed base.
- U.S. instrument demand returned to normal growth patterns, with strong repeat purchases from academic, government, and biopharma customers.
- +7 more takeaways